Novel compounds active against Leishmania major

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 474-479

  St George, Stephanie ^a   Bishop, Jeanette V ^b   Titus, Richard G ^b   Selitrennikoff, Claude P ^a  

^a MycoLogics Inc   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SCREENING; IN VITRO STUDY; LEISHMANIA MAJOR; LEISHMANIA TARENTOLAE; LEISHMANIASIS; LIBRARY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; BACTERIA; FUNGI; LEISHMANIA MAJOR; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 31944436271     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.474-479.2006     Document Type: Article

References (23)

1. Alvar, J., C. Canavate, B. Guterriez-Solar, et al. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
2. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
3. Berman, J. D. 1985. Experimental chemotherapy of leishmaniasis: a critical review, p. 112-138. In K. P. Chang and R. S. Bray (ed.), Leishmaniasis. Elsevier, Amsterdam, The Netherlands.
4. 125Sb]sodium stibogluconate by Leishmania mexicana amazonensis and Leishmania donovani in vitro. Comp. Biochem. Physiol. C 68:95-98.
5. del Rayo Camacho, M., J. D. Phillipson, S. L. Croft, P. Rock, S. J. Marshall, and P. L. Schiff, Jr. 2002. In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei. Phytother. Res. 16:432-436.
6. Escobar, P., V. Yardley, and S. L. Croft. 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45:1872-1875.
7. Gaskin, A., P. Schantz, J. Jackson, et al. 2002. Visceral leishmaniasis in a New York foxhound kennel. J. Vet. Intern. Med. 16:34-44.
8. Gebre-Hiwot, A., G. Tadesse, S. L. Croft, and D. Frommel. 1992. An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop. 51:237-245.
9. Herwaldt, B., and J. Berman. 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46:296-306.
10. Magill, A., M. Grogl, R. Gasser, et al. 1993. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N. Engl. J. Med. 328:1383-1387.
11. Nabors, G. S., L. C. Afonso, J. P. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92:3142-3146.
12. Neal, R. A., S. Allen, N. McCoy, P. Olliaro, and S. L. Croft. 1995. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35:577-584.
13. Neal, R. A., and S. L. Croft. 1984. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
14. Neva, F. A., and H. W. Brown. 1994. Blood and tissue protozoa of human beings, p. 57. In F. A. Neva, and H. W. Brown (ed.), Basic clinical parasitology. Appleton & Lange, Norwalk, Conn.
15. Pehoushek, J. F., D. M. Quinn, and W. P. Crum. 2004. Cutaneous leishmaniasis in soldiers returning from deployment to Iraq. J. Am. Acad. Dermatol. 51(5 Suppl.):S197-S200. (Erratum, 51:1040.)
16. Sereno, D., P. Holzmuller, and L. Lemesre. 2000. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Acta Trop. 74:25-31.
17. Smith, A. C., V. Yardley, J. Rhodes, and S. L. Croft. 2000. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 44:1494-1498.
18. Sundar, S., F. Rosenkaimer, M. Makharia, et al. 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352:1821-1823.
19. Titus, R. G., A. Kelso, and J. A. Louis. 1984. Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin. Exp. Immunol. 55:157-165.
20. Winship, K. 1987. Toxicity of antimony and its compounds. Adverse Drug React. Acute Poisoning Rev. 6:67-90.
21. World Health Organization. 1995. Report on the consultative meeting on Leishmania/HIV co-infection, Rome, Italy, 6 to 7 September 1994. WHO/ Leish/95.35/1995. World Health Organization, Geneva, Switzerland.
22. World Health Organization. 2001. WHO information by topics or disease. World Health Organization, Geneva, Switzerland. [Online.] http://www.who .int/emc/diseases/leish/index.html.
23. Wortmann, G., R. Miller, C. Oster, et al. 2002. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin. Infect. Dis. 35:261-267.